Evidence map›Paper›PMID 30415317›Full record

ReviewWorld journal of urology2019

The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside.

Jonathan J Duplisea, Sharada Mokkapati, Devin Plote, Kimberly S Schluns, David J McConkey, Seppo Yla-Herttuala, Nigel R Parker, Colin P Dinney

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of urology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Strategies for Overcoming Immune Evasion in Bladder Cancer.International journal of molecular sciences · 2024
    Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Intravesical Gene Therapy.The Urologic clinics of North America · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jonathan J DupliseaDepartment of Urology, The University of Texas MD Anderson Cancer Center, 1220 Holcombe Blvd Floor 7, Houston, TX, 77030, USA.
Sharada MokkapatiDepartment of Urology, The University of Texas MD Anderson Cancer Center, 1220 Holcombe Blvd Floor 7, Houston, TX, 77030, USA.
Devin PloteDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kimberly S SchlunsDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
David J McConkeyJames Buchanan Brady Urological Institute, Johns Hopkins Greenberg Bladder Cancer Institute, Johns Hopkins University, School of Medicine, Baltimore, MD, USA.
Seppo Yla-HerttualaA.I.Virtanen Institute, University of Eastern Finland and Gene Therapy Unit, Kuopio University Hospital, Kuopio, Finland.
Nigel R ParkerHamesman Ltd., London, UK.
Colin P DinneyDepartment of Urology, The University of Texas MD Anderson Cancer Center, 1220 Holcombe Blvd Floor 7, Houston, TX, 77030, USA. cdinney@mdanderson.org.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Targeting Ral GTPases in Bladder CancerP50CA091846 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DINNEY, COLIN P.N., MCCONKEY, DAVID J. · 2001 to 2018
$37.4M
NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA091846NCI NIH HHS P50CA091846NIH HHS P30CA016672
6 · The paper itself

Abstract

background and purposeBCG unresponsive bladder cancer is an inherently resistant disease state for which the preferred treatment is radical cystectomy. To date, no effective intravesical therapies exist for patients who possess these resistant tumors. For this reason, many research groups are actively investigating/testing novel therapeutic agents to aid in bladder preservation for this patient population. This review article describes our 15-year experience developing and testing IFN-based gene therapy.

methodsA comprehensive review was performed of all studies pertaining to IFN-based gene therapy for non-muscle invasive bladder cancer from 2003 to 2018. RESULTS AND

conclusionsOver the past two decades, gene therapy has evolved into a powerful tool in our fight against cancer. After overcoming the initial barriers associated with gene delivery to the bladder, we have made significant strides forward in developing this novel therapeutic strategy for the treatment of this inherently resistant disease state. Our results to date are very encouraging; however, much work lies ahead to better understand and optimize this novel approach for treating non-muscle invasive bladder.

Indexed as

Adjuvants, ImmunologicBCG VaccineBiomedical ResearchClinical Trials as TopicGenetic TherapyHumansInterferonsTreatment FailureUrinary Bladder NeoplasmsAdjuvants, ImmunologicBCG VaccineInterferonsBCG unresponsive bladder cancerGene therapyInstiladrinInterferon-α

Identifiers

PMID30415317
PMCPMC6511323

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.